PCM
CHRS icon

Piermont Capital Management’s Coherus Oncology CHRS Stock Holding History

Piermont Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-19,060
Closed -$537K – 250
2016
Q4 		$537K Buy
+19,060
New +$533K 0.12% 220

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Piermont Capital Management's CHRS Position: Q1 2017 in Review

Piermont Capital Management sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 19,060 shares — an estimated $537K sold.

Piermont Capital Management first reported a position in CHRS in Q4 2016 and held it in 1 quarter. The position peaked at $537K in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • Piermont Capital Management reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
  • Piermont Capital Management sold 19,060 Coherus Oncology shares in Q1 2017, an estimated $537K.
  • Piermont Capital Management first reported a position in Coherus Oncology in Q4 2016 and held it in 1 quarter.
  • Piermont Capital Management's Coherus Oncology position peaked at $537K in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Piermont Capital Management's 13F filing for Q1 2017, filed 11 May 2017.